DAR-0100A

A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia.

Authors: Abi-Dargham A, Carter CS, Cho RY, Girgis RR, Glass A, Kegeles LS, Lieberman JA, Slifstein M, Thompson JL, Van Snellenberg JX, Wall M

Journal: Journal of Psychopharmacology

BACKGROUND: Evidence from preclinical and human studies indicates the presence of reduced dopamine-1 receptor (D1R) signaling in the cortex, where D1Rs predominate, in patients with schizophrenia (SCZ), which may contribute to their cognitive deficits. Furthermore, studies […]

Back to Publications